◈ Nootpedia
Compact view
Research pass: medium Compound OPTIONAL-ADD LOW

Tetramethoxyluteolin

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict OPTIONAL-ADD LOW

Plausible mast-cell-driven neuroinflammation thesis (relevant to MMA subconcussive impact context) and a genuine PK improvement over plain luteolin, but the entire human evidence base is preliminary and largely from one investigator group (Theoharides). For Dylan as PRN tool around heavy sparring blocks it is conceivable; as a daily core item it is not justified yet.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    OPTIONAL-ADD-PRN

    low. Reasonable PRN tool for heavy sparring blocks given the subconcussive-impact context; not as daily core.

  • 30-50, executive maintenance
    OPTIONAL-ADD-PRN

    low. Low-priority; CRP-driven decision.

  • 50+, mild cognitive decline
    OPTIONAL-ADD

    low. Plausible neuroinflammatory contribution to MCI; trial individually if hs-CRP elevated.

  • Anxiety-prone
    M

    — mast-cell-anxiety links exist but compound is not anxiolytic.

  • High athletic load, tested status
    OPTIONAL-ADD-PRN

    Not banned. Useful for impact-sport recovery.

  • Sleep-disordered
    N
  • Recovery-focused (post-injury, post-illness)
    STRONG-CANDIDATE

    within MCAS/mast-cell-driven phenotypes (post-COVID, post-mold).

  • Strength/anabolic-focused
    I
▸ Subjective experience (deep)

Per Algonot (Luteolux / NeuroProtek brands) and patient reports:

  • Onset over days to weeks (not acute)
  • Reduction in "mast-cell brain fog" (subjective; relevant to MCAS/MCAS-adjacent populations)
  • Clearer thinking, less head pressure under inflammatory triggers
  • Generally well-tolerated, no felt acute effect

For a non-MCAS user (like Dylan in a healthy state), expect minimal felt effect except potentially in the days following heavy contact training when neuroinflammatory load is highest.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Not expected — works at cell-stabilization level, not receptor agonism
  • Recommended cycle: PRN or daily; no cycling required
  • Reset protocol if needed: Not applicable
▸ Stacking deep dive

Synergistic with

  • luteolin (parent): Same family; some products combine for "spectrum" effect
  • quercetin: Another mast-cell stabilizer with different binding profile; common combo in NeuroProtek
  • palmitoylethanolamide (PEA-Ultra): Different mechanism (PPAR-α, endocannabinoid system) but parallel anti-neuroinflammatory effect
  • apigenin: Both flavonoids, both anti-inflammatory; logical co-administration

Avoid stacking with

  • Heavy anticoagulants — additive antiplatelet caution

Neutral / safe co-administration

All V4 stack compounds; curcumin pairs naturally as anti-inflammatory.

▸ Drug interactions deep dive
  • Mild CYP3A4 inhibition reported for parent luteolin; methylated analog less characterized
  • Theoretical antiplatelet additive effect — relevant only if on warfarin or DOAC
▸ Pharmacogenomics

Unstudied for the methylated analog. Parent luteolin metabolism varies with UGT1A1 and SULT polymorphisms — practically inapplicable here because methylation bypasses those enzymes.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
OTC supplement Algonot (Luteolux, NeuroProtek) $40-60 / 60 caps Medium Theoharides-affiliated brand; the de facto source for the methylated form
OTC supplement Generic luteolin (parent compound) $15-30 / 60 caps High NOT the same molecule; much weaker bioavailability

Confirm any "tetramethyl-luteolin" / "methoxy-luteolin" product is actually the methylated analog and not the base flavonoid.

▸ Biomarkers to track (deep)
  • Baseline (before starting): hs-CRP, IL-6, tryptase if MCAS suspected
  • During use: hs-CRP every 8-12 weeks; track subjective brain-fog scale
  • Post-cycle: Not applicable
▸ Controversies / open debates Live debate
  • Most of the human and head-to-head in-vitro data on tetramethoxyluteolin specifically come from a single investigator (Theoharides) with commercial ties to the Algonot product line. Independent replication is limited. Mechanism is plausible; magnitude of clinical effect is uncertain.
  • Whether methylation actually improves CNS efficacy or just plasma exposure is not fully resolved — methoxy groups can also alter target affinity.
  • "Mast cell activation syndrome" itself is a contested clinical entity; treatment populations are heterogeneous.
▸ Verdict change log
  • 2026-05-06 — Initial verdict: OPTIONAL-ADD-PRN low. PRN tool around heavy training blocks; not justified as daily core. Re-evaluate after Dylan's bloodwork (hs-CRP, IL-6) lands June 2026.
▸ Open questions / gaps Open
  • Independent replication of Theoharides head-to-head luteolin vs methylated-luteolin potency claims
  • Real human PK and brain penetration (most data are rodent)
  • Whether mast-cell stabilization measurably reduces post-sparring neuroinflammatory markers in healthy combat athletes — no trial exists
▸ Sources (full, with our context)
Back to compact view